Trial Profile

An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Mecbotamab vedotin (Primary) ; Ozuriftamab vedotin (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms IPROC

Most Recent Events

07 Nov 2025 According to Coherus BioSciences media release, in October 2025, the Cancer Research Institute announced the first patient enrolled in the third cohort of the ongoing Immunotherapy Platform Study.
30 Sep 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
30 Sep 2025 Planned primary completion date changed from 30 Jun 2025 to 30 Jun 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com